Valneva Continues To Expand COVID-19 Vaccine Candidate Trials

Valneva SE VALN has commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K.
Topline results from the trial, dubbed Cov-Compare, are expected early in Q4 of 2021 and are intended to form the basis for potential regulatory approval in adults.
Valneva also started to provide boosters to volunteers in its Phase 1/2 VLA2001-201 trial.
The booster shot will be provided to each volunteer six months after the initial vaccination.
The planned expansion of the trials will support future approval in further age groups, in addition to adults.
Valneva shares plunged more than 40% after Britain canceled its contract for about 100 million doses of the Company's vaccine.
Related Content: Valneva Shares Plunge As UK Terminates COVID-19 Vaccine Contract: What You Need To Know.
"Valneva continues discussions with the European Commission regarding a potential VLA2001 supply contract," the Company said in a statement.
In the statement, Chief Executive Thomas Lingelbach added, "We're confident that many countries, and regulators, will want to have the opportunity to consider our inactivated COVID-19 vaccine."
Price Action: VALN stock is up 7.34% at $33.77 during the premarket session on the last check Thursday.

Momentum74.36

Growth-

Quality-

Value55.70

Short

Medium

Long